首页 > 市场调查报告书 > 製药

药物开发

市场调查报告书

商品编码

1733258

2026 年至 2032 年药物研发市场（按药物类型、技术、最终用户和地区划分）

Drug Discovery Market By Drug Type (Small-Molecule Drugs, Biologic Drugs), Technology (High Throughput Screening, Pharmacogenomics), End-User (Pharmaceutical Companies, Contract Research Organizations (CROs)), & Region for 2026-2032.

出版日期: 2025年04月30日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

药物研发市场评估 - 2026-2032

预计到 2024 年，药物研发市场的估值将超过 531 亿美元，这得益于疾病数量的增加、技术进步、学术界、产业界和政府之间的合作、个人化医疗以及有利的监管政策。

筛检技术、计算建模以及 CRISPR/Cas9 基因编辑等平台的进步使得这个过程更有效率、更具成本效益。个人化医疗的转变和人口老化也促进了市场的成长，预计到 2032 年市场规模将达到 942.3 亿美元，2026 年至 2032 年的复合年增长率为 8.20%。

药物研发市场定义/概述

药物发现是一个跨学科的过程，涉及生物学、化学、药理学和计算科学，以识别和开发新药。它首先是目标识别，然后是目标检验和高效能筛检技术。化合物的功效、副作用和药物动力学特性均经过优化。这些化合物在进行临床试验之前要经过临床前测试，包括体外和体内实验。临床测试至关重要，在人体上分三个阶段进行。监管机构在核准之前会审查数据并确定该药物是否安全有效。为患者带来新的治疗方法需要科学家、临床医生、监管机构和产业伙伴之间的合作。

是什么推动了药物研发市场的发展？

药物研发是一个快速发展的领域，受到多种因素的影响。高性能筛检、基因组学、蛋白质组学和结构生物学等领域的技术进步彻底改变了这个过程，使研究人员能够更有效地识别新目标并设计药物。

人工智慧和机器学习等计算方法透过预测药物-标靶相互作用和优化化合物特性来加速这一进程。学术界、工业界和政府机构之间的合作促进了创新并加速了药物发现。加快审查途径和灵活核准标准等监管变化将鼓励对药物研发的投资。由基因组学和生物标记识别推动的个人化医疗将改善治疗结果并减少副作用。

药物再利用是一种经济高效且省时的药物发现方法。创业投资、政府机构和製药公司的投资将刺激创新并支持基础设施发展。新兴感染疾病和慢性病等全球健康挑战推动了特定治疗领域的投资和研究重点。以病人为中心的方法，包括病人权益团体和参与式研究模式，确保药物开发符合病人的需求和偏好。获得大规模生物医学数据使研究人员能够获得见解、确定新的药物标靶并更有效地检验治疗假设。

药物研发市场的成长面临哪些障碍？

药物发现是一个复杂的过程，面临各种挑战。这包括目标识别和检验、高性能筛检、先导优化、临床前测试、临床试验设计和招募、监管障碍、成本和资金筹措、专利保护和智慧财产权等。透过严格的科学研究确定相关的分子标靶对于药物发现工作的成功至关重要。

高通量筛检耗时且成本高，因此开发更有效的筛检方法至关重要。先导化合物是一项复杂的任务，需要大量的药物化学知识。临床前测试评估了先导化合物在疾病模型中的安全性和有效性，但在可预测性和对人体生物学的适用性方面可能面临挑战。

临床试验设计和招募可能具有挑战性，尤其是对于罕见疾病或患者群体有限的疾病。核准流程和资金保障等监管障碍可能会减缓药物开发进度。成本和资金筹措也是主要挑战，特别是对于结果不确定的早期计划。

保护智慧财产权对于增强技术创新奖励、吸引投资至关重要。应对这些挑战需要跨领域合作、创新技术和适应性策略，以加速药物发现过程并为患者提供安全有效的治疗方法。

Advances in screening techniques, computational modelling, and platforms like CRISPR/Cas9 gene editing have made the process more efficient and cost-effective. The shift towards personalized medicine and the growing aging population also contribute to the market's growth and is expected to reach USD 94.23 Billion by 2032, growing at a CAGR of 8.20% from 2026 to 2032.

Drug Discovery Market: Definition/ Overview

Drug discovery is a multidisciplinary process involving biology, chemistry, pharmacology, and computational science to identify and develop new medications. It starts with target identification, followed by target validation and high-throughput screening techniques. Compounds are optimized for efficacy, side effects, and pharmacokinetic properties. These compounds undergo preclinical studies, including in vitro and in vivo experiments, before advancing to clinical trials. Clinical trials are crucial, conducted in three phases involving human participants. Regulatory agencies review data to determine drug safety and effectiveness for approval. Collaboration between scientists, clinicians, regulatory authorities, and industry partners is essential for bringing new treatments to patients.

What Factors are Propelling the Drug Discovery Market?

Drug discovery is a rapidly evolving field that has been influenced by various factors. Technological advancements in areas like high-throughput screening, genomics, proteomics, and structural biology have revolutionized the process, allowing researchers to identify new targets and design drugs more efficiently.

Computational methods, such as artificial intelligence and machine learning, accelerate the process by predicting drug-target interactions and optimizing compound properties. Collaborative research between academia, industry, and government institutions fosters innovation and accelerates drug discovery efforts. Regulatory changes, such as expedited review pathways and flexible approval criteria, encourage investment in drug discovery research. Personalized medicine, facilitated by genomics and biomarker identification, improves treatment efficacy and reduces adverse effects.

Drug repurposing offers a cost-effective and time-efficient approach to drug discovery. Investment from venture capital firms, government agencies, and pharmaceutical company's fuels innovation and supports infrastructure development. Global health challenges, such as emerging infectious diseases and chronic conditions, drive investment and research focus in specific therapeutic areas. Patient-centric approaches, including patient advocacy groups and participatory research models, ensure that drug development aligns with patient needs and preferences. Access to large-scale biomedical data enables researchers to derive insights, identify novel drug targets, and validate therapeutic hypotheses more effectively.

What are the Barriers Impeding the Growth of the Drug Discovery Market?

Drug discovery is a complex process that involves various challenges. These include target identification and validation, high-throughput screening, lead optimization, preclinical studies, clinical trial design and recruitment, regulatory hurdles, cost and funding, and patent protection and intellectual property. Identifying relevant molecular targets through rigorous scientific investigation is crucial for the success of drug discovery efforts.

High-throughput screening is time-consuming and costly, and developing more efficient screening methods is essential. Lead optimization is a complex task that requires extensive medicinal chemistry efforts. Preclinical studies assess the safety and efficacy of lead compounds in disease models, but can face challenges related to predictability and translatability to human biology.

Clinical trial design and recruitment pose challenges, especially for rare diseases or conditions with limited patient populations. Regulatory hurdles, such as navigating the approval process and securing funding, can delay the drug development timeline. Cost and funding are also significant challenges, especially for early-stage projects with uncertain outcomes.

Protecting intellectual property rights is crucial for incentivizing innovation and attracting investment. Addressing these challenges requires collaboration across disciplines, innovative technologies, and adaptive strategies to accelerate the drug discovery process and deliver safe and effective treatments to patients.

Category-Wise Acumens

Which Drug Type has the Highest Market Share in the Drug Discovery Market?

Small molecule drugs are therapeutic agents with diverse chemical structures and mechanisms of action, with a significant market share in the drug discovery market. These drugs target chronic diseases like cardiovascular diseases, diabetes, and central nervous system disorders. Cardiovascular drugs, such as statins and antihypertensive agents, have a significant market share due to their high prevalence.

Diabetes drugs, like metformin and insulin analogues, command a substantial portion of the market due to the rising incidence of diabetes worldwide. Central nervous system disorders, like antidepressants, antipsychotics, and anxiolytics, address conditions like depression, schizophrenia, anxiety disorders, and neurodegenerative diseases like Alzheimer's and Parkinson's. Oncology drugs also have a substantial market share due to the growing prevalence of cancer and the continuous development of targeted therapies and chemotherapy agents. Overall, small molecule drugs targeting chronic diseases like cardiovascular diseases, diabetes, and cancer have the highest market share in the drug discovery market.

How Pharmaceutical Companies are Expanding the Drug Discovery Market?

Pharmaceutical companies are expanding the drug discovery market through various strategies and innovations. They invest heavily in R&D to identify novel therapeutic targets and develop new drugs using advanced technologies like high-throughput screening, computational modeling, and artificial intelligence. They are also focusing on personalized medicine approaches, tailoring treatments to individual patients based on factors like genetic makeup and lifestyle.

Partnerships and collaborations with academic institutions, biotechnology startups, and other industry players help access new technologies and reduce the cost and risk associated with drug development. Pharmaceutical companies are exploring new therapeutic areas and indications, such as rare diseases, oncology, and neurodegenerative disorders, to address unmet medical needs and expand their market reach.

They are also expanding into emerging markets like Asia-Pacific, Latin America, and Africa, where there is growing demand for healthcare services and increased access to medicines. This strategy allows pharmaceutical companies to tap into new patient populations and drive market growth.

Country/Region-wise Acumens

Which Region Holds the Largest Market Share in Drug Discovery Market?

North America holds the largest market share in the drug discovery market due to its robust ecosystem of pharmaceutical and biotechnology companies, research institutions, academic centers, and government agencies. The region's leading pharmaceutical hubs, such as the San Francisco Bay Area, Boston-Cambridge, and San Diego, foster innovation and collaboration among industry players, academia, and research organizations.

The US Food and Drug Administration provides clear guidelines and pathways for drug development, ensuring rigorous standards for safety, efficacy, and quality assurance. North America's substantial investment in research and development fuels drug discovery initiatives, driving innovation and the development of novel therapeutics across various disease areas.

Additionally, the highly skilled workforce, including scientists, researchers, clinicians, and engineers, enables the region to tackle complex scientific challenges and pioneer groundbreaking approaches in drug development. The presence of world-class academic and research institutions also fosters collaboration and knowledge exchange, accelerating the pace of drug discovery and contributing to the region's leadership in the global pharmaceutical market.

What Factors are Driving the Rapid Expansion of the Asia-Pacific in Drug Discovery Market?

The Asia-Pacific region is experiencing a significant growth in the pharmaceutical industry, driven by rising healthcare expenditures, chronic diseases, and improved healthcare access. This has led to increased investment in drug discovery and development activities by both domestic and multinational pharmaceutical companies. The region is also witnessing a surge in biotechnology innovation and entrepreneurship, supported by government initiatives, venture capital funding, and collaborations with academia and research institutions. The region's rich biodiversity offers access to diverse biological resources, which researchers and pharmaceutical companies use for natural product screening, bio-prospecting, and drug discovery efforts.

Advanced research infrastructure, including state-of-the-art laboratories, research centers, and technology parks, is being built in countries like Japan, South Korea, Singapore, China, and India. Government support and incentives are also being implemented to attract investment and foster innovation in the biopharmaceutical sectors.

Rising collaboration and partnerships between pharmaceutical companies, research institutions, academia, and government agencies are driving innovation and knowledge exchange in drug discovery. The Asia-Pacific region's diverse population, including diverse ethnic groups and an increasing elderly population, provides access to large patient populations for clinical trials, biomarker discovery, and personalized medicine initiatives. Overall, the Asia-Pacific is a key player in global drug discovery efforts.

Competitive Landscape

The market is fiercely competitive, with established companies leveraging advanced technology, high-quality products, and strong brand image to drive revenue growth. They employ strategies like research, development, mergers, and technological innovations to expand their product portfolios.

Some of the prominent players operating in the drug discovery market are:

Fizer, Inc.

GlaxoSmithKline PLC

Merck & Co., Inc.

Agilent Technologies, Inc.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Bayer AG

Abbott Laboratories, Inc.

AstraZeneca PLC

Shimadzu Corp

Latest Developments

In October 2022: Verge Genomics, a clinical-stage and technology-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced dosing the first subject in its Phase 1 clinical trial of VRG50635.

In October 2022: NGM Bio released topline results from the CATALINA Phase 2 Trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration.

1 INTRODUCTION OF GLOBAL DRUG DISCOVERY MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL DRUG DISCOVERY MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL DRUG DISCOVERY MARKET, BY DRUG TYPE

5.1 Overview
5.2 Small Molecule Drugs
5.3 Biologic Drugs

6 GLOBAL DRUG DISCOVERY MARKET, BY TECHNOLOGY

6.1 Overview
6.2 High Throughput Screening
6.3 Pharmacogenomics
6.4 Nanotechnology

7 GLOBAL DRUG DISCOVERY MARKET, BY END-USERS

7.1 Overview
7.2 Pharmaceutical Companies
7.3 Contract Research Organizations (CROs)

8 GLOBAL DRUG DISCOVERY MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL DRUG DISCOVERY MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market ranking
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES

10.1 Pfizer Inc.
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 GlaxoSmithKline PLC
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Merck & Co. Inc.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Agilent Technologies Inc.
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Eli Lilly and Company
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 F. Hoffmann-La Roche Ltd
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Bayer AG
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Abbott Laboratories Inc
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 AstraZeneca PLC
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Shimadzu Corp
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments

11 APPENDIX

11.1 Related Research

02-2729-4219

+886-2-2729-4219

License/价格

2026 年至 2032 年药物研发市场（按药物类型、技术、最终用户和地区划分）

Drug Discovery Market By Drug Type (Small-Molecule Drugs, Biologic Drugs), Technology (High Throughput Screening, Pharmacogenomics), End-User (Pharmaceutical Companies, Contract Research Organizations (CROs)), & Region for 2026-2032.

药物研发市场评估 - 2026-2032

是什么推动了药物研发市场的发展？

药物研发市场的成长面临哪些障碍？

目录

第一章：全球药物研发市场简介

第二章执行摘要

第三章：已验证的市场研究调查方法

第四章全球药物研发市场展望

第五章全球药物研发市场（依药物类型）

第六章 全球药物研发市场（依技术）

第七章 全球药物研发市场（依最终用户划分）

第八章全球药物研发市场（按地区）

第九章全球药物研发市场的竞争格局

第十章 公司简介

第十一章 附录

Drug Discovery Market Valuation - 2026-2032